Purple Biotech (PPBT) EPS (Basic) (2014 - 2026)

Purple Biotech (PPBT) has 13 years of EPS (Basic) data on file, last reported at $0.0 in Q1 2026.

• On a quarterly basis, EPS (Basic) fell 100.0% year-over-year to $0.0 in Q1 2026; TTM through Mar 2026 was $0.03, a 99.89% decrease from a year earlier, with the FY2025 full-year figure at -$0.03, up 99.94% from the prior year.
• EPS (Basic) for Q1 2026 stood at $0.0, down from $0.02 in the prior quarter.
• Over the last five years, EPS (Basic) for PPBT reached as high as $83.07 in Q1 2022 and fell as low as $0.0 in Q1 2026.
• Historically, EPS (Basic) has averaged $31.58 across 5 years, with a median of $34.13 in 2024.
• Across the five-year window, EPS (Basic) surged 152605.42% in 2022 and sank 100.0% in 2026, its largest moves.
• Year by year, EPS (Basic) stood at $66.49 in 2022, then tumbled by 34.39% to $43.63 in 2023, then tumbled by 94.27% to $2.5 in 2024, then tumbled by 99.02% to $0.02 in 2025, then sank by 99.63% to $0.0 in 2026.
• Per Business Quant data, the three most recent EPS (Basic) figures were $0.0 in Q1 2026, $0.02 in Q4 2025, and $7.95 in Q3 2025.